Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Cash & Current Investments for 5 consecutive years, with $165.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 32.03% year-over-year to $165.6 million, compared with a TTM value of $165.6 million through Dec 2025, down 32.03%, and an annual FY2025 reading of $165.6 million, down 32.03% over the prior year.
  • Cash & Current Investments was $165.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $352.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $379.5 million in Q1 2025 and bottomed at $141.1 million in Q1 2024.
  • Average Cash & Current Investments over 5 years is $217.3 million, with a median of $191.3 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments plummeted 44.91% in 2022, then soared 169.03% in 2025.
  • Year by year, Cash & Current Investments stood at $182.2 million in 2021, then increased by 4.61% to $190.6 million in 2022, then grew by 8.27% to $206.4 million in 2023, then grew by 18.05% to $243.6 million in 2024, then plummeted by 32.03% to $165.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for KNSA at $165.6 million in Q4 2025, $352.1 million in Q3 2025, and $192.0 million in Q2 2025.